What does ASPIRE mean in PHYSIOLOGY
Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) is a clinical trial that seeks to assess the efficacy of aspirin in reducing the risk of recurrent venous thromboembolism (VTE). VTE involves blood clots forming in the veins, usually in the legs, leading to major health concerns such as pulmonary embolism. ASPIRE is a double-blinded study examining whether low-dose aspirin can help reduce rates of recurrence among those who have had VTE in the past. The study has enrolled more than 12,000 participants from over 30 countries and it is sponsored by Bayer AG.
ASPIRE meaning in Physiology in Medical
ASPIRE mostly used in an acronym Physiology in Category Medical that means Aspirin to Prevent Recurrent Venous Thromboembolism (Study)
Shorthand: ASPIRE,
Full Form: Aspirin to Prevent Recurrent Venous Thromboembolism (Study)
For more information of "Aspirin to Prevent Recurrent Venous Thromboembolism (Study)", see the section below.
» Medical » Physiology
Aim Of The Study
The primary objective of this research was to determine if using small daily doses of aspirin could reduce the rate of recurrent VTE in patients who have already experienced a first episode or had been diagnosed with VTE at least three months prior to enrollment in this study. It also aimed at determining whether there were any differences between men and women when it came to how effective aspirin would be in preventing VTE relapse. Finally, the team wanted to see if any correlations between aspirin use and cardiovascular events or bleeding incidents could be determined during the course of this research project.
Essential Questions and Answers on Aspirin to Prevent Recurrent Venous Thromboembolism (Study) in "MEDICAL»PHYSIOLOGY"
What is the Aspire Study?
The Aspire study is a research program conducted by Harvard Medical School and Brigham and Women's Hospital that evaluates the effectiveness of daily low-dose aspirin in reducing the risk of recurrent venous thromboembolism (VTE).
Who is eligible for the Aspire Study?
Eligibility for the Aspire Study includes adults 18 years of age or older with a diagnosis of VTE who are willing to take daily low-dose aspirin.
What is Venous Thromboembolism?
Venous thromboembolism (VTE) is a form of blood clotting that can block veins, typically in the legs, but can travel to other parts of the body, such as lungs, arms and brain.
How long will I need to take part in the Aspire Study?
Participants in the Aspire Study may receive study medication for up to 12 months. A final evaluation visit will occur 6 months after discontinuation of study medication.
What type of medication do I need to take as part of this study?
Participants in the Aspire Study will be given daily low-dose aspirin (81 mg). There are no other medications or supplements required.
What are possible risks involved with participating in this study?
Possible risks associated with taking daily low-dose aspirin include gastrointestinal discomfort, nausea, vomiting, and bleeding problems. Additional risks may be outlined in study documents provided at screening and at subsequent visits.
Are there any costs associated with my participation in this study?
The costs associated with participation in the Aspire Study are minimal; all related medical exams and procedures are provided free of charge. However, it is important to note that your insurance provider might not cover any aspect related to your participation in this trial.
Will I receive compensation for taking part in this trial?
Yes! Individuals who participate in the Aspire Study may receive compensation for time/travel expenses like parking vouchers or meal reimbursements. Additionally there may be additional funds depending on their participation level.
Final Words:
The results of ASPIRE showed that daily low dose aspirin use does provide some protection against recurrent venous thromboembolic events for patients who have already had one episode or been diagnosed with VTE within three months prior to participating in this study. It also showed that no gender differences were seen regarding response rate when it came to taking aspirin for prevention purposes. Although minor bleeding events did occur during the course care of these patients, overall rates were low as compared with other studies focusing on patients taking similar medications for prevention purposes over long periods time.